OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. D'Amato on the Emerging Role of Next-Generation Sequencing in Sarcoma

April 11th 2020

Gina Z. D'Amato, MD, discusses the emerging role of next-generation sequencing in sarcoma.

Dr. Mesa on Unanswered Questions Regarding JAK Inhibitors in Myelofibrosis

April 11th 2020

Ruben Mesa, MD, discusses unanswered questions regarding JAK inhibitors in myelofibrosis.

Dr. Chase on Toxicities With Niraparib in Ovarian Cancer

April 11th 2020

Dana Chase, MD, FACOG, discusses the safety profile of niraparib as frontline maintenance therapy in ovarian cancer.

Dr. Tagawa on Targeting PSMA in Prostate Cancer

April 10th 2020

Scott T. Tagawa, MD, MS, discusses the utility of beta and alpha emitters in targeting PSMA in prostate cancer.

Dr. Armstrong on the Utility of Pamiparib and Other PARP Inhibitors in Prostate Cancer

April 10th 2020

Andrew J. Armstrong, MD, discusses the utility of pamiparib and other PARP inhibitors in prostate cancer.

Dr. Rossetti on the Fast Track Designation of Momelotinib in Myelofibrosis

April 10th 2020

James M. Rossetti, DO, discusses the FDA’s decision to grant momelotinib a fast track designation for use in patients with intermediate- or high-risk myelofibrosis who previously received a JAK inhibitor.

Dr. Michaelis on Unanswered Questions in Myelofibrosis Treatment

April 10th 2020

Laura C. Michaelis, MD, discusses the direction of future myelofibrosis research.

Dr. Bekaii-Saab on the Impact of COVID-19 on Telemedicine

April 10th 2020

Tanios S. Bekaii-Saab, MD, FACP, discusses the impact of the novel coronavirus 2019 on telemedicine.

Dr. Chung on the Importance of Genomic Testing in Pancreatic Cancer

April 9th 2020

Vincent Chung, MD, discusses the importance of genomic testing in pancreatic cancer.

Dr. Woyach on the Utility of Time-Limited Therapies in CLL

April 9th 2020

Jennifer Woyach, MD, discusses the utility of time-limited therapies in chronic lymphocytic leukemia.

Dr. Gunderson on the Use of PARP Inhibitors in All-Comers With Ovarian Cancer

April 9th 2020

Camille C. Gunderson, MD, assistant professor of gynecologic oncology, Stephenson Cancer Center, discusses the use of PARP inhibitors in all-comers with ovarian cancer.

Dr. Gupta Shares Updates From the Frontlines of the Battle Against COVID-19

April 9th 2020

Shilpa Gupta, MD, shares updates from the frontlines and discusses how she is handling the COVID-19 pandemic.

Dr. Hamilton on Using pCR to Classify Risk in HER2+ Breast Cancer

April 9th 2020

Erika P. Hamilton, MD, director of the Breast Cancer and Gynecologic Research Program and principal investigator at Sarah Cannon Research Institute, discusses the use of pathologic complete response (pCR) as a way to classify risk status in HER2-positive breast cancer.

Dr. Villa on the Use of BR as Induction Therapy in MCL

April 9th 2020

Diego Villa, MD, MPH, clinical associate professor, Division of Medical Oncology, Department of Medicine, The University of British Columbia, discusses the use of bendamustine and rituximab (Rituxan) as induction therapy in mantle cell lymphoma (MCL).

Dr. Comerci on the Use of Laparoscopy in Ovarian Cancer

April 9th 2020

John T. Comerci, MD, associate professor, University of Pittsburgh School of Medicine, and director of Gynecologic Oncology, University of Pittsburgh Medical Center Passavant Hospital, discusses the use of laparoscopy in ovarian cancer.

Dr. Antonarakis on Trial Examining Sipuleucel-T Plus Radium-223 in Bone-Metastatic CRPC

April 9th 2020

Emmanuel S. Antonarakis, MBBCh, discusses the design of a randomized phase II study of sipuleucel-T with or without radium-223 dichloride in men with asymptomatic bone-metastatic castrate-resistant prostate cancer.

Dr. Agarwal on PFS2 Data From the TITAN Trial in mCSPC

April 9th 2020

Neeraj Agarwal, MD, discusses data from a posthoc analysis of the phase III TITAN trial in patients with metastatic castration-sensitive prostate cancer.

Dr. McKay on the Utility of Radium-223 in the Treatment of mCRPC

April 9th 2020

Rana R. McKay, MD, discusses the utility of radium-223 in metastatic castration-resistant prostate cancer.

Dr. Snyder on Tools to Improve Use of Allogeneic Stem Cell Transplant in Myelofibrosis

April 8th 2020

David S. Snyder, MD, discusses tools to improve the use of allogeneic stem cell transplant in myelofibrosis.

Dr. O'Malley on Research With Immunotherapy in Ovarian Cancer

April 8th 2020

David O’Malley, MD, discusses the current state of immunotherapy in ovarian cancer.